Template:Isosorbide dinitrate: Difference between revisions
Jump to navigation
Jump to search
(Created page with "{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; ! style="padding: 0 5px; font-size: 100%; background:#F8F8...") |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Isosorbide dinitrate|{{fontcolor|#6C7B8B|Isosorbide dinitrate}}]]''''' | ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Isosorbide dinitrate|{{fontcolor|#6C7B8B|Isosorbide dinitrate}}]]''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ISORDIL<sup>®</sup> FDA Package Insert | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate indications and usage|Indications and Usage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate indications and usage|Indications and Usage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate dosage and administration|Dosage and Administration]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate dosage and administration|Dosage and Administration]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate contraindications|Contraindications]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate contraindications|Contraindications]] | ||
| Line 17: | Line 15: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate drug interactions|Drug Interactions]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate drug interactions|Drug Interactions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate overdosage|Overdosage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate overdosage|Overdosage]] | ||
| Line 25: | Line 21: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate clinical pharmacology|Clinical Pharmacology]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate clinical pharmacology|Clinical Pharmacology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate clinical studies|Clinical Studies]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate clinical studies|Clinical Studies]] | ||